Biotech company announces initiatives to accelerate path to breakeven by end of 2026.
Cell programing bio-tech firm Ginkgo Bioworks Holdings last week announced results for Q124, with overall revenue down 53% year over year at US$38 million.
In its cell engineering division, revenue was down 18% year over…
Join for free* to continue reading.
You’ll get access to all Alt-Meat has to offer including full access to our web content devoted to the meat alternatives market.
Already a member? Click here to login>>.
*Free for qualified recipients